Browsing by title

Primidone blocks RIPK1-driven cell death and inflammation.

Riebeling, T; Jamal, K; Wilson, R; Kolbrink, B; von Samson-Himmelstjerna, FA; et al. (2020-12-03)

The receptor-interacting serine/threonine protein kinase 1 (RIPK1) is a key mediator of regulated cell death and inflammation. Recent studies suggest that RIPK1 inhibition would fundamentally improve the therapy of ...

Principal component analysis fosr fast and model-free denoising of multi b-value diffusion-weighted MR images.

Gurney-Champion, OJ; Collins, DJ; Wetscherek, A; Rata, M; Klaassen, R; et al. (2019-05-17)

Despite the utility of tumour characterisation using quantitative parameter maps from multi-b-value diffusion-weighted MRI (DWI), clinicians often prefer the use of the image with highest diffusion-weighting (b-value), for ...

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

Bellmunt, J; Kheoh, T; Yu, MK; Smith, MR; Small, EJ; et al. (2016-05)

The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).To determine if prior endocrine therapy duration is an indicator ...

Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.

Loveday, C; Sud, A; Jones, ME; Broggio, J; Scott, S; et al. (2020-08-27)

Objective To evaluate the impact of faecal immunochemical testing (FIT) prioritisation to mitigate the impact of delays in the colorectal cancer (CRC) urgent diagnostic (2-week-wait (2WW)) pathway consequent from the ...

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Buckley, HL; Collinson, FJ; Ainsworth, G; Poad, H; Flanagan, L; et al. (2019-11-14)

BACKGROUND:The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the ...

Privileged Structures and Polypharmacology within and between Protein Families.

Meyers, J; Chessum, NEA; Ali, S; Mok, NY; Wilding, B; et al. (2018-12)

Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 (<b>1</b>) and the ...

Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.

Beneforti, L; Dander, E; Bresolin, S; Bueno, C; Acunzo, D; et al. (2020-07)

ETV6-RUNX1 (E/R) fusion gene, arising in utero from translocation t(12;21)(p13:q22), is the most frequent alteration in childhood acute lymphoblastic leukemia (ALL). However, E/R is insufficient to cause overt leukemia ...

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

May-Wilson, S; Sud, A; Law, PJ; Palin, K; Tuupanen, S; et al. (2017-10)

Background While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate ...

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.

Crabb, SJ; Birtle, AJ; Martin, K; Downs, N; Ratcliffe, I; et al. (2017-10)

Background Docetaxel and prednisolone chemotherapy (DP) extends survival in metastatic castration resistant prostate cancer (mCRPC). However, emergent clinical resistance is almost inevitable. AKT pathway activation is ...

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Banerjee, S; Califano, R; Corral, J; de Azambuja, E; De Mattos-Arruda, L; et al. (2017-07)

Background Burnout in health care professionals could have serious negative consequences on quality of patient care, professional satisfaction and personal life. Our aim was to investigate the burnout prevalence, work and ...

Professor John Francis 'Jack' Fowler D.Sc. (1925-2016) Obituary

Yarnold, J; Hoskin, P; Hendry, J; Jones, B (ELSEVIER SCIENCE LONDON, 2017-03-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence.

Rebuzzi, SE; Banna, GL; Murianni, V; Damassi, A; Giunta, EF; et al. (2021-11-03)

In recent years, the treatment landscape of urothelial carcinoma has significantly changed due to the introduction of immune checkpoint inhibitors (ICIs), which are the standard of care for second-line treatment and ...

Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.

Borelli, B; Fontana, E; Giordano, M; Antoniotti, C; Lonardi, S; et al. (2021-03-03)

Introduction The consensus molecular subtypes (CMS) demonstrated prognostic value in metastatic colorectal cancer (mCRC). Similarly, a prognostic impact was suggested for the pre-consensus CRCAssigner (CRCA) classifier in ...

Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer

De Mattos-Arruda, L; Olmos, D; Tabernero, J (FUTURE MEDICINE LTD, 2011-12)

Circulating tumor cells (CTCs) and circulating free DNA (cfDNA) have been studied as promising prognostic and predictive tumor-derived biomarkers in the bloodstream of patients with gastrointestinal malignancies because ...

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Kennedy, OJ; Kicinski, M; Valpione, S; Gandini, S; Suciu, S; et al. (ELSEVIER SCI LTD, 2022-04-01)

BACKGROUND: β-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β-adrenoreceptor ...

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs, CS; Muro, K; Tomasek, J; Van Cutsem, E; Cho, JY; et al. (2017-06-16)

Purpose To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer.Materials and ...

Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.

Rugo, HS; Cristofanilli, M; Loibl, S; Harbeck, N; DeMichele, A; et al.

Background This analysis investigated whether baseline characteristics affect the survival benefit derived from palbociclib-fulvestrant and the optimal timing of cyclin-dependent kinase 4/6 inhibitor therapy for advanced ...

Publications Repository

Publications Repository